46. 悪性関節リウマチ Malignant rheumatoid arthritis Clinical trials / Disease details

臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224

12 trials found

diseases per page:

Showing 1 to 10 of 12 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03636984 (ClinicalTrials.gov)	August 24, 2018	13/8/2018	Efficacy and Safety Study of Anbainuo in Chinese Patients With RA/AS in the Real World	Efficacy and Safety Study of Anbainuo in Chinese Patients With Rheumatoid Arthritis/ Ankylosing Spon ...	Rheumatoid Arthritis;Ankylosing Spondylitis	Drug: recombinant TNF-a receptor: IgG Fc fusion protein	Zhejiang Hisun Pharmaceutical Co. Ltd.	NULL	Not yet recruiting	18 Years	N/A	All	1000		NULL
2	NCT03589833 (ClinicalTrials.gov)	July 2018	5/7/2018	Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA	Effectiveness and Safety of Tumor Necrosis Factor Receptor FusionProtein(Yisaipu) Combined With Trip ...	Arthritis, Rheumatoid	Drug: Tripterygium Wilfordii;Drug: Methotrexate;Drug: Yisaipu	Peking Union Medical College Hospital	NULL	Unknown status	18 Years	65 Years	All	504	Phase 2	China
3	EUCTR2017-001944-36-ES (EUCTR)	21/05/2018	10/10/2017	Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid Arthritis	A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoi ...	Rheumatoid Arthritis MedDRA version: 20.0;Level: HLT;Classification code 10039075;Term: Rheumatoid a ...	Product Name: AMG592 INN or Proposed INN: AMG 592 Other descriptive name: RECOMBINANT FACTOR FC FUSION ...	Amgen Inc	NULL	Not Recruiting			Female: yes Male: yes	137	Phase 1;Phase 2	United States;Czech Republic;Mexico;Poland;Spain;Romania;Australia;Bulgaria;Germany;United Kingdom;N ...
4	EUCTR2017-001944-36-BG (EUCTR)	13/03/2018	24/10/2017	Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid Arthritis	A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoi ...	Rheumatoid Arthritis MedDRA version: 20.0;Level: HLT;Classification code 10039075;Term: Rheumatoid a ...	Product Name: AMG592 INN or Proposed INN: N/A Other descriptive name: RECOMBINANT FACTOR FC FUSIONPROT ...	Amgen Inc	NULL	Not Recruiting			Female: yes Male: yes	153	Phase 1;Phase 2	United States;Czech Republic;Mexico;Spain;Poland;Romania;Australia;Bulgaria;Germany;United Kingdom;N ...
5	NCT03016013 (ClinicalTrials.gov)	September 2016	8/1/2017	A Study of the Efficacy and Safety of TACI-antibody FusionProtein Injection (RC18) in Subjects With ...	A Phase III Study of RC18,a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusi ...	Moderate and Severe RheumatoId Arthritis	Biological: Placebo plus MTX;Biological: RC18 160 mg plus MTX	RemeGen	NULL	Recruiting	18 Years	65 Years	All	480	Phase 3	China
6	NCT02882087 (ClinicalTrials.gov)	October 2015	24/8/2016	A Study of the Efficacy and Safety of TACI-antibody FusionProtein Injection (RC18) in Subjects With ...	A Phase II, Placebo-Controlled, Multicenter, Dynamic Randomized, Double Blind Trial of RC18, a Recom ...	Moderate and Severe Rheumatoid Arthritis	Drug: Placebo plus MTX;Drug: RC18 160 mg plus MTX	RemeGen	NULL	Terminated	18 Years	65 Years	All	60	Phase 2	China
7	NCT02076659 (ClinicalTrials.gov)	September 2011	24/2/2014	Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients	A Dose-finding, Pharmacokinetic Phase I Study of the Human Monoclonal Antibody-cytokine FusionProtei ...	Rheumatoid Arthritis	Drug: F8IL10;Drug: Methotrexate	Philogen S.p.A.	NULL	Completed	18 Years	75 Years	All	36	Phase 1	Italy
8	ChiCTR1900024107	2010-09-29	2019-06-26	A randomized, controlled, open label, multicenter clinical trial to evaluate the efficacy and safety ...	A randomized, controlled, open label, multicenter clinical trial to evaluate the efficacy and safety ...	Active Rheumatoid Arthritis	A:Treatment of Yisaipu combined with methotrexatefor 52 weeks;B:Treatment of Yisaipu combined with m ...	Chinese Academy of Medical Sciences & Peking Union Medical College Hospital	NULL	Completed	18	60	Both	A:30;B:30;C:30;	Phase 4	China
9	NCT00012506 (ClinicalTrials.gov)	October 1999	10/3/2001	The Safety and Efficacy of a Tumor Necrosis Factor Receptor FusionProtein on Uveitis Associated With ...		Uveitis;Arthritis, Juvenile Rheumatoid	Drug: TNFR:Fc	National Eye Institute (NEI)	NULL	Recruiting	2 Years	18 Years	Both		Phase 3	United States
10	NCT00001862 (ClinicalTrials.gov)	February 1999	3/11/1999	TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis	The Safety and Efficacy of a Tumor Necrosis Factor Receptor FusionProtein on Uveitis Associated With ...	Juvenile Rheumatoid Arthritis;Uveitis	Drug: Enbrel	National Eye Institute (NEI)	NULL	Completed	N/A	N/A	Both	15	Phase 2	United States

First Previous1 2Next Last